Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1986 1
1999 2
2000 2
2001 1
2003 2
2005 1
2008 1
2010 1
2011 1
2014 5
2016 1
2017 1
2018 1
2019 1
2020 2
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Fibrolamellar Carcinoma"
Page 1
Therapeutic Efficacy of Temsirolimus in a Patient-derived Model of Metastatic Fibrolamellar Hepatocellular Carcinoma.
Leiting JL, Hernandez MC, Bergquist JR, Yonkus JA, Abdelrahman AM, Torbenson MS, Tran NH, Halfdanarson TR, Graham RP, Smoot RL, Truty MJ. Leiting JL, et al. In Vivo. 2023 Sep-Oct;37(5):1940-1950. doi: 10.21873/invivo.13290. In Vivo. 2023. PMID: 37652480 Free PMC article.
BACKGROUND/AIM: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare tumor presenting in younger patients without chronic liver disease. ...RESULTS: PDX models were successfully generated from metastatic FLHCC, which closely recapitulated the original tum …
BACKGROUND/AIM: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare tumor presenting in younger patients without chronic …
Liver transplantation for malignancies.
Eghtesad B, Aucejo F. Eghtesad B, et al. J Gastrointest Cancer. 2014 Sep;45(3):353-62. doi: 10.1007/s12029-014-9590-2. J Gastrointest Cancer. 2014. PMID: 24604263 Review.
Liver transplantation (LT) has become an acceptable and effective treatment for selected patients with hepatocellular carcinoma with excellent outcomes. More recently, LT has been tried in different primary and secondary malignancies of the liver. ...
Liver transplantation (LT) has become an acceptable and effective treatment for selected patients with hepatocellular carcinoma with …
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
Al Zahrani A, Alfakeeh A. Al Zahrani A, et al. J Med Case Rep. 2021 Mar 16;15(1):132. doi: 10.1186/s13256-021-02695-8. J Med Case Rep. 2021. PMID: 33722275 Free PMC article.
On the other hand, the prognosis remains poor for locally advanced and metastatic fibrolamellar hepatocellular carcinoma. Many reports suggested a limited benefit from systemic chemotherapy. ...Currently, there are no reports yet on the use of atezolizumab wi …
On the other hand, the prognosis remains poor for locally advanced and metastatic fibrolamellar hepatocellular carcinoma …
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening.
Lalazar G, Requena D, Ramos-Espiritu L, Ng D, Bhola PD, de Jong YP, Wang R, Narayan NJC, Shebl B, Levin S, Michailidis E, Kabbani M, Vercauteren KOA, Hurley AM, Farber BA, Hammond WJ, Saltsman JA 3rd, Weinberg EM, Glickman JF, Lyons BA, Ellison J, Schadde E, Hertl M, Leiting JL, Truty MJ, Smoot RL, Tierney F, Kato T, Wendel HG, LaQuaglia MP, Rice CM, Letai A, Coffino P, Torbenson MS, Ortiz MV, Simon SM. Lalazar G, et al. Cancer Discov. 2021 Oct;11(10):2544-2563. doi: 10.1158/2159-8290.CD-20-0872. Epub 2021 Jun 14. Cancer Discov. 2021. PMID: 34127480 Free PMC article.
To repurpose therapeutics for fibrolamellar carcinoma (FLC), we developed and validated patient-derived xenografts (PDX) from surgical resections. ...A high-throughput functional drug screen found primary and metastatic FLC were vulnerable to clinically avail …
To repurpose therapeutics for fibrolamellar carcinoma (FLC), we developed and validated patient-derived xenografts (PDX) from …
Liver transplantation for malignancy: current treatment strategies and future perspectives.
Hackl C, Schlitt HJ, Kirchner GI, Knoppke B, Loss M. Hackl C, et al. World J Gastroenterol. 2014 May 14;20(18):5331-44. doi: 10.3748/wjg.v20.i18.5331. World J Gastroenterol. 2014. PMID: 24833863 Free PMC article. Review.
In the following, liver transplantation was considered ideal for complete tumor resection and potential cure from primary hepatic malignancies. Several reports of liver transplantation for primary and metastatic liver cancer however showed disappointing results and the str …
In the following, liver transplantation was considered ideal for complete tumor resection and potential cure from primary hepatic malignanci …
Hepatocellular carcinoma: an update.
Dominguez-Malagón H, Gaytan-Graham S. Dominguez-Malagón H, et al. Ultrastruct Pathol. 2001 Nov-Dec;25(6):497-516. doi: 10.1080/019131201753343539. Ultrastruct Pathol. 2001. PMID: 11783914 Review.
Fibrolamellar carcinoma has a characteristic histological picture and ultrastructurally oncocytic features. Neuroendocrine granules and combination of HCC with bile duct carcinoma are seen by electron microscopy....
Fibrolamellar carcinoma has a characteristic histological picture and ultrastructurally oncocytic features. Neuroendocrine gra …
Hepatic neoplasia: selected clinical aspects.
Schiff L. Schiff L. Semin Roentgenol. 1983 Apr;18(2):71-4. doi: 10.1016/0037-198x(83)90004-4. Semin Roentgenol. 1983. PMID: 6191395 Review.
Fibrolamellar carcinoma, which characteristically develops in adolescents and young adults, occurs with equal sex incidence. ...Clinical manifestations of hepatoma have been divided into 5 groups: frank cancer (62.7%), acute abdominal cancer (8%), febrile can …
Fibrolamellar carcinoma, which characteristically develops in adolescents and young adults, occurs with equal sex incidence. . …
Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma.
Gottlieb S, O'Grady C, Gliksberg A, Kent P. Gottlieb S, et al. Oncology. 2021;99(5):310-317. doi: 10.1159/000513358. Epub 2021 Mar 9. Oncology. 2021. PMID: 33690232
INTRODUCTION: There are no standard systemic therapies for the treatment of fibrolamellar carcinoma (FLC), as surgery remains the only definitive option. ...Overall objective response (clinical remission + partial response) was 50% and tumor control rate ( …
INTRODUCTION: There are no standard systemic therapies for the treatment of fibrolamellar carcinoma (FLC), as surgery remains …
Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S, Magliocca J, Sellers M, Roccaro G, Zheng W, Pectasides M, Draper A, Guadagno J, El-Rayes B, Akce M. Kang S, et al. Oncol Res Treat. 2022;45(7-8):430-437. doi: 10.1159/000524872. Epub 2022 May 10. Oncol Res Treat. 2022. PMID: 35537414 Free article.
INTRODUCTION: Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a history of liver disease. ...The patient developed biopsy-proven recurrent FLC with multiple liver lesions but without any distant metastatic …
INTRODUCTION: Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a histo …
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Yau T, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. Lancet Gastroenterol Hepatol. 2024. PMID: 38364832 Clinical Trial.
BACKGROUND: The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. ...The secondary endpoint was progression-free survival in all patients ran …
BACKGROUND: The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previous …
30 results